Results 111 to 120 of about 50,655 (275)
P91: MOVING BEYOND SIMPLE CLINICAL SEVERITY SCALES FOR HEREDITARY ANGIOEDEMA: DEVELOPMENT AND PILOT TESTING OF A MULTIFACTORIAL ASSESSMENT TOOL [PDF]
, 2022 openalex +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and Objective Despite the availability of guidelines and effective escalation therapies, chronic spontaneous urticaria (CSU) is often inadequately treated in Germany. Implementation science can help to transfer evidence‐based care into practice.
Ralph von Kiedrowski +10 more
wiley +1 more source
Institutional Incidence of Severe tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents
Critical Care Research and Practice, 2018 Introduction. Tissue plasminogen activator (tPA) is commonly used in ischemic cerebral vascular accidents (CVAs). tPA is generally well tolerated; however, orolingual angioedema is a well-documented adverse effect. Angioedema is generally mild, transient,
Matthew Sczepanski, Paul Bozyk
doaj +1 more source
Population Pharmacokinetic/Pharmacodynamic Modeling of Donidalorsen, an Antisense Oligonucleotide in Development for Prophylaxis of Hereditary Angioedema [PDF]
CPT Pharmacometrics Syst PharmacolABSTRACT Hereditary angioedema (HAE) is a rare disorder linked to kallikrein‐kinin system dysregulation, which leads to uncontrolled activation of plasma prekallikrein. Donidalorsen is an antisense oligonucleotide designed to selectively degrade prekallikrein messenger RNA and thereby reduce prekallikrein production.
Diep J +7 more
europepmc +2 more sources
Diabetes, Obesity and Metabolism, EarlyView.Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj +6 more
wiley +1 more source
Food as a trigger for abdominal angioedema attacks in patients with hereditary angioedema [PDF]
, 2018 Urs C. Steiner +6 more
openalex +1 more source
The FEBS Journal, EarlyView.Angiotensin I‐converting enzyme (ACE) contains two catalytic domains (nACE and cACE) and is a key therapeutic target for hypertension and cardiovascular disease. Current ACE inhibitors (ACEi) nonselectively inhibit both domains, causing adverse effects. Selective inhibition requires an understanding of domain‐specific binding.
Kyle S. Gregory +3 more
wiley +1 more source
Zdorovʹe Rebenka, 2014 Hereditary angioedema — a rare disease caused by a congenital deficiency of C1-inhibitor. Clinical manifestations of the disease — recurrent episodes of angioedema, which manifest in childhood or adolescence, more often localized in the subcutaneous ...
A.P. Volokha
doaj +1 more source